at the same time, berkshire exited small remaining stakes in , you heard john najarian say it u.s.n. berkshire hathaway class a has shares not a typo, are just about at half a million dollars here, 499, 500 a share that's because its never split and it is up three-quarters of a percent which means it's up $ 3,600. m m & a trouble of the horizon. the stock has fallen 14% after the federal trade commission sued to block amgen's acquisition of the pharmaceutical company for $28 billion and an in junction was filed that if approved a judge could prevent the deal from closing entirely. the agency says the deal would allow amgen to "en trench the monopoly positions of horizon's thyroid eye disease and gout drugs" specifically those two. horizon therapeutics says that it intends to work with the court on a schedule that would allow the transaction to close by mid-december, but this ftc doesn't like deals here. we've got amgen down 2.5%. the news is reverberating through the entire biotech space you see this often happen the f tc campaign cracks down on big pharma mergers like pfizer's acq